Nuclear receptor subfamily 1 group D member (NR1D1), also known as Rev-erbA-α, is highly expressed in the liver, adipose tissue, brain and skeletal muscle.

Trypto Therapeutics GmbH scientists have discovered novel tryptophan hydroxylase (TPH) inhibitors, which are being developed for the treatment of colorectal cancer.